02588nam 2200493 450 991080980350332120200520144314.01-118-91693-X1-118-91694-81-118-91692-1(CKB)4330000000007479(MiAaPQ)EBC4862949(DLC) 2016056137(Au-PeEL)EBL4862949(CaPaEBR)ebr11386890(CaONFJC)MIL1012237(OCoLC)965446691(PPN)223995754(EXLCZ)99433000000000747920170615h20172017 uy 0engurcnu||||||||rdacontentrdamediardacarrierOral bioavailability assessment basics and strategies for drug discovery and development /Ayman F. El-KattanHoboken, New Jersey :Wiley Blackwell,2017.©20171 online resource (455 pages) illustrationsWiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods1-118-91669-7 Includes bibliographical references and index.Drug pharmacokinetics and toxicokinetics -- GIT anatomy and physiology and drug oral bioavailability : impact of species differences -- Drug routes of excretion -- Physicochemical and biopharmaceutical properties that affect drug absorption of compounds absorbed by passive diffusion -- Physicochemical and biopharmaceutical factors affecting hepatic/intestinal first pass effect -- Impact of intestinal efflux transporters on oral absorption -- Impact of influx transporters on drug -- Extended Clearance Classification System (ECCS) and its utility in predicting clearance rate determining step in drug discovery -- In vitro and in situ approaches to measure intestinal permeability and efflux transporters -- In silico approaches to predict intestinal permeability -- In vivo preclinical approaches to deconvolute the contribution of first pass effect from oral absorption -- In vitro approaches to assess haptic metabolism and first pass effect -- The utility of ECCS as a roadmap to improve oral bioavailability of new molecular entities : industrial perspective.Dental pharmacologyDental pharmacology.615.1/9El-Kattan Ayman F.1668535MiAaPQMiAaPQMiAaPQBOOK9910809803503321Oral bioavailability assessment4029200UNINA